4-(2-氯乙氧基)苯甲醛 | 54373-15-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-氯乙氧基)苯甲醛
• 中文别名: 依曲替酯；苯壬四烯酯；N-(2-溴乙氧基)苯甲醛
• 英文名称: 4-(2-chloroethoxy)benzaldehyde
• CAS: 54373-15-8
• 化学式: C₉H₉ClO₂
• mdl: MFCD00043699
• 分子量: 184.622
• InChiKey: HBHHMVNKQWECIS-UHFFFAOYSA-N

物化性质

• 熔点：
  25-30°C
• 沸点：
  138-142 °C(Press: 2 Torr)
• 密度：
  1.2246 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2913000090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温和干燥环境

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(2-Chloroethoxy)benzaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(2-Chloroethoxy)benzaldehyde
CAS number: 54373-15-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9ClO2
Molecular weight: 184.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-氯乙氧基)苯甲醛 在 palladium on activated charcoal 哌啶 、 氢气 、 potassium carbonate 、 溶剂黄146 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 3.0h， 生成 [[4-[2-（6-苯甲酰基-2-氧代-3（2H）-苯并噻唑基）乙氧基]苯基]甲基]-1,3-propanedioicaciddimethylester
  参考文献：
  名称：

  Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARγ agonists

  摘要：

  A series of 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles has been synthesized and tested for PPAR gamma agonist activity. SAR were developed and revealed that 6-acyl-2(3H)-benzothiazolone derivatives with 1,3-dicarbonyl group were the most potent. IP administration of compound 22 exhibited comparable levels of glucose and triglyceride correction to PO administration of rosiglitazone in the oblob mouse studies. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.07.029
• 作为产物：
  描述：

  1-氯-2-碘乙烷 、 对羟基苯甲醛 在 caesium carbonate 、 potassium iodide 作用下， 以 丁酮 为溶剂， 反应 1.0h， 生成 4-(2-氯乙氧基)苯甲醛
  参考文献：
  名称：

  SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF

  摘要：

  这项发明涉及一般式(I)的1-氨基邻苯二酮衍生物：其中A、B、L、R、R1、R2、R3、R4、R5和R7如本文所定义。该发明还涉及所述化合物的制备及其治疗用途。

  公开号：

  US20090124624A1

文献信息

• Effect of Oxime Ether Incorporation in Acyl Indole Derivatives on PPAR Subtype Selectivity
  作者：Morgan Le Naour、Veronique Leclerc、Amaury Farce、Daniel-Henri Caignard、Nathalie Hennuyer、Bart Staels、Valérie Audinot-Bouchez、Jean-Albert Boutin、Michel Lonchampt、Catherine Dacquet、Alain Ktorza、Pascal Berthelot、Nicolas Lebegue

  DOI：10.1002/cmdc.201200316

  日期：2012.12

  balanced activity for both subtypes. Herein we report the discovery, synthesis, and optimization of a new series of α‐ethoxyphenylpropionic acid bearing 5‐ or 6‐substituted indoles. The incorporation of oxime ethers on the carbonyl portion of the benzoyl group can bring the PPARα/γ potency ratio equal to or slightly greater than one, as is the case for compounds 20 c and 21 a. Compound 20 c shows high efficacy

  同时激活过氧化物酶体增殖物激活受体（PPAR）亚型α和γ的化合物具有在单个药物活性分子中有效治疗血脂异常和2型糖尿病（T2D）的潜力。选择性添加PPARα活性有望克服选择性PPARγ激动剂经常观察到的副作用，例如水肿和体重增加，从而导致两种亚型的双重PPARα/γ激动剂均具有平衡的活性。本文中，我们报告发现，合成和优化了一系列新的带有5或6个取代的吲哚的α-乙氧基苯基丙酸。在苯甲酰基的羰基部分上掺入肟醚可以使PPARα/γ效力比等于或略大于1，就像化合物20c和21a的情况一样。化合物20c的表现出高效力在OB / OB T2D和血脂异常，类似于罗格列酮和替格列扎的小鼠模型，但与体重增加一个显著增加。与此相反，化合物21，作为双PPARα/γ活化剂小于有力20c中，显示了一个有趣的药理学特性，因为它引起在相对于体重的参考化合物的降低。
• Asymmetric Synthesis of Chiral 1, <scp>3‐Disubstituted</scp> Allylsilanes <i>via</i> Copper(I)‐Catalyzed 1, <scp>4‐Conjugate</scp> Silylation of α, <scp>β‐Unsaturated</scp> Sulfones and Subsequent <scp>Julia‐Kocienski</scp> Olefination
  作者：Xian‐Liang Wang、Xing‐Hao Yin、Jun‐Zhao Xiao、Xue‐Shun Jia、Liang Yin

  DOI：10.1002/cjoc.202100101

  日期：2021.7

  array of chiral allylsilanes in moderate yields. More interestingly, a one-pot asymmetric synthesis with high synthetic efficiency is successfully realized. Utility of the prepared chiral 1,3-disubsituted allylsilanes is demonstrated in the asymmetric allylation of both aldehyde and aldimine. Finally, an interesting “match and mismatch” phenomenon is observed in the asymmetric allylation of chiral aldehydes

  手性 1,3-二取代烯丙基硅烷的一般合成是通过铜 (I) 催化的 α,β-不饱和砜的不对称 1,4-共轭硅烷化和随后的 Julia-Kocienski 烯化建立的。通过修饰 McQuade 的 NHC 配体，以高对映选择性实现了具有广泛底物范围的催化不对称共轭硅烷化。以下Julia-Kocienski 烯化在室温下顺利进行，以中等产率提供一系列手性烯丙基硅烷。更有趣的是，成功实现了具有高合成效率的一锅不对称合成。在醛和醛亚胺的不对称烯丙基化中证明了制备的手性 1,3-二取代烯丙基硅烷的效用。最后，在手性醛的不对称烯丙基化中观察到了一个有趣的“匹配和错配”现象。
• Multicomponent formation route to a new class of oxygen-based 1,3-dipoles and the modular synthesis of furans
  作者：Huseyin Erguven、Cuihan Zhou、Bruce A. Arndtsen

  DOI：10.1039/d1sc04088j

  日期：——

  generated by the multicomponent reaction of aldehydes, acid chlorides and the phosphonite PhP(catechyl). These 1,3-dipoles are formally cyclic tautomers of simple Wittig-type ylides, where the angle strain and moderate nucleophilicity in the catechyl-phosphonite favor their cyclization and also direct 1,3-dipolar cycloaddition to afford single regioisomers of substituted products. Coupling the generation

  通过醛、酰氯和亚膦酸酯 PhP（儿茶基）的多组分反应，可以生成一类新的含磷 1,3-偶极子。这些 1,3-偶极子是简单 Wittig 型叶立德的形式上的环状互变异构体，其中儿茶基-亚膦酸酯中的角应变和适度的亲核性有利于它们的环化，并且还直接进行 1,3-偶极环加成以提供取代产物的单一区域异构体。偶极子的产生与 1,3-偶极环加成相结合，提供了一种独特的模块化途径，从可用醛、酰氯和炔烃的组合中获得呋喃，并独立控制所有四个取代基。
• New heterocyclic oxime compounds
  申请人：Leclerc Veronique

  公开号：US20050026973A1

  公开（公告）日：2005-02-03

  Compounds of formula (I): wherein: X represents oxygen or sulphur or a group CH 2 or R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description, A represents an alkylene chain as defined in the description, B represents alkyl or alkenyl substituted by a group or R 9 , or B represents a group or R 9 , D represents a benzene, pyridine, pyrazine, pyrimidine or pyridazine nucleus. Medicaments

  式(I)的化合物：其中：X代表氧或硫或基团CH2或R1、R2、R3、R4、R5和R6如描述中所定义，A代表描述中所定义的烷基链，B代表被基团或R9取代的烷基或烯基，或者B代表基团或R9，D代表苯、吡啶、吡嗪、嘧啶或吡啉核。药物
• [EN] PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND/OR SMARCA4<br/>[FR] CHIMÈRES CIBLANT LA PROTÉOLYSE (PROTAC) SERVANT D'AGENTS DE DÉGRADATION DE SMARCA2 ET/OU SMARCA4
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2020078933A1

  公开（公告）日：2020-04-23

  The present invention encompasses compounds of formula (I) wherein the groups R1,A, G, LK and t have the meanings given in the claims and specification, their use as degraders of SMARCA2 and/or SMARCA4, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式（I）中R1、A、G、LK和t所表示的基团，其用作SMARCA2和/或SMARCA4的降解剂，含有此类化合物的药物组合物以及它们作为药物/医用的用途，特别是作为治疗和/或预防肿瘤疾病的药剂/医疗用途的代理。

表征谱图